Stock GBSX MARIZYME, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Marizyme, Inc.

Equities

GBSX

US5703721028

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 03:03:30 2024-04-18 pm EDT 		5-day change 1st Jan Change
0.095 USD 0.00% Intraday chart for Marizyme, Inc. 0.00% -5.09%
Feb. 06 Marizyme, Inc. Announces Resignation of Julie Kampf from the Board of Directors CI
2023 Marizyme, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 0.5109 37.2 10.33 89.72 71.33 21.28
Enterprise Value (EV) 1 0.4593 37.2 10.33 88.14 69.21 26.14
P/E ratio -0.9 x -51 x -9.73 x -11.3 x -5.8 x -0.56 x
Yield - - - - - -
Capitalization / Revenue 5.05 x 1,843 x - 455 x 339 x 91.1 x
EV / Revenue 4.54 x 1,843 x - 447 x 329 x 112 x
EV / EBITDA - - - -16,922,638 x -7,884,495 x -2,154,234 x
EV / FCF 0.97 x -59.3 x 38 x -64.2 x -29.8 x -3.38 x
FCF Yield 103% -1.69% 2.63% -1.56% -3.36% -29.6%
Price to Book 0.24 x 0.44 x 0.37 x 1.98 x 1.5 x 1.22 x
Nbr of stocks (in thousands) 1,101 19,581 19,859 35,888 40,298 40,528
Reference price 2 0.4640 1.900 0.5200 2.500 1.770 0.5250
Announcement Date 6/21/18 3/5/19 4/15/20 4/15/21 3/31/22 3/24/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 0.1012 0.0202 - 0.1971 0.2103 0.2335
EBITDA - - - -5.208 -8.778 -12.13
EBIT 1 -0.1249 -0.2471 -1.058 -5.8 -8.821 -12.97
Operating Margin -123.46% -1,224.2% - -2,941.93% -4,195.09% -5,556.59%
Earnings before Tax (EBT) 1 -0.5705 -0.2487 -1.058 -5.845 -11 -38.17
Net income 1 -0.5705 -0.2487 -1.058 -5.845 -11 -38.17
Net margin -563.88% -1,232.19% - -2,964.99% -5,230.16% -16,346.18%
EPS 2 -0.5182 -0.0373 -0.0534 -0.2216 -0.3051 -0.9371
Free Cash Flow 1 0.4747 -0.6269 0.2718 -1.372 -2.326 -7.732
FCF margin 469.18% -3,105.52% - -696.22% -1,106.11% -3,311.68%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 6/21/18 3/5/19 4/15/20 4/15/21 3/31/22 3/24/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - 4.86
Net Cash position 1 0.05 0 0 1.58 2.12 -
Leverage (Debt/EBITDA) - - - - - -0.4005 x
Free Cash Flow 1 0.47 -0.63 0.27 -1.37 -2.33 -7.73
ROE (net income / shareholders' equity) -23.2% -1.62% -3.72% -15.9% -23.7% -117%
ROA (Net income/ Total Assets) -2.66% -0.98% -2.31% -9.58% -9.75% -15.5%
Assets 1 21.43 25.32 45.79 61.03 112.8 246.4
Book Value Per Share 2 1.970 4.280 1.420 1.260 1.180 0.4300
Cash Flow per Share 2 0.0500 0 0 0.0800 0.1000 0.0100
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 6/21/18 3/5/19 4/15/20 4/15/21 3/31/22 3/24/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
MARIZYME, INC. Stock Marizyme, Inc.
-5.09% 4.43M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. GBSX Stock
  4. Financials Marizyme, Inc.